NextCell Pharma AB (OSTO:NXTCL) Cyclically Adjusted Book per Share: kr1.55 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NXTCL NextCell Pharma AB OSTO:NXTCL
42 GF Score
Price kr1.01
GF Value kr0.90
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is NextCell Pharma AB Cyclically Adjusted Book per Share?

NextCell Pharma AB OSTO:NXTCL -0.20% 42 Cyclically Adjusted Book per Share is kr1.55 as of Dec. 2025. GuruFocus rates OSTO:NXTCL with a GF Score™ of 42/100 and a GF Value™ of kr0.90 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

NextCell Pharma AB's adjusted book value per share for the three months ended in Dec. 2025 was kr0.454. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr1.55 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-27), NextCell Pharma AB's current stock price is kr1.01. NextCell Pharma AB's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was kr1.55. NextCell Pharma AB's Cyclically Adjusted PB Ratio of today is 0.65.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of NextCell Pharma AB was 1.02. The lowest was 0.44. And the median was 0.78.


NextCell Pharma AB  (OSTO:NXTCL) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NextCell Pharma AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.01/1.55
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of NextCell Pharma AB was 1.02. The lowest was 0.44. And the median was 0.78.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


NextCell Pharma AB Cyclically Adjusted Book per Share Related Terms


NextCell Pharma AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for NextCell Pharma AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB Cyclically Adjusted Book per Share Chart

NextCell Pharma AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NextCell Pharma AB Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.55

OSTO:NXTCL vs VRTX, REGN, RVMD: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, NextCell Pharma AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCell Pharma AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NextCell Pharma AB's Cyclically Adjusted PB Ratio falls into.


OSTO:NXTCL
42GF Score
NextCell Pharma AB OSTO:NXTCL
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NextCell Pharma AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NextCell Pharma AB's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.454/133.3900*133.3900
=0.454

Current CPI (Dec. 2025) = 133.3900.

NextCell Pharma AB Quarterly Data

Book Value per Share CPI Adj_Book
201508 0.650 99.829 0.869
201605 0.000 100.914 0.000
201608 0.450 100.968 0.594
201611 0.000 101.517 0.000
201702 0.376 102.037 0.492
201705 0.569 102.679 0.739
201708 1.480 103.138 1.914
201711 1.231 103.413 1.588
201802 0.896 103.678 1.153
201805 0.657 104.632 0.838
201808 0.391 105.197 0.496
201811 0.809 105.443 1.023
201902 0.609 105.641 0.769
201905 0.351 106.895 0.438
201908 0.800 106.716 1.000
201911 0.669 107.345 0.831
202002 0.522 106.742 0.652
202005 0.341 106.882 0.426
202008 0.793 107.571 0.983
202011 0.628 107.549 0.779
202102 3.559 108.190 4.388
202105 3.557 108.838 4.359
202108 3.448 109.780 4.190
202111 3.300 111.069 3.963
202202 3.065 112.834 3.623
202205 2.851 116.746 3.257
202208 2.655 120.573 2.937
202211 2.450 123.803 2.640
202302 2.188 126.321 2.310
202305 1.937 128.034 2.018
202308 1.740 129.560 1.791
202311 1.515 130.958 1.543
202402 1.283 132.046 1.296
202405 1.080 132.818 1.085
202408 0.925 132.052 0.934
202411 0.815 133.000 0.817
202502 0.703 133.744 0.701
202505 0.369 133.064 0.370
202508 0.596 133.440 0.596
202512 0.454 133.390 0.454

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr1.55 mean?
NextCell Pharma AB (OSTO:NXTCL) has a Cyclically Adjusted Book per Share of kr1.55 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on NextCell Pharma AB and its competitors.
Is NextCell Pharma AB's Cyclically Adjusted Book per Share too high?
NextCell Pharma AB's current Cyclically Adjusted Book per Share is kr1.55. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
NextCell Pharma AB's Cyclically Adjusted Book per Share of kr1.55 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on NextCell Pharma AB and its competitors. NextCell Pharma AB's current Cyclically Adjusted Book per Share is kr1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (OSTO:NXTCL) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.90, compared to a current price of kr1.01 — trading 12.2% above its estimated fair value. The current Cyclically Adjusted Book per Share is kr1.55. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For NextCell Pharma AB (OSTO:NXTCL), the current Cyclically Adjusted Book per Share is kr1.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NextCell Pharma AB (OSTO:NXTCL) Overvalued in 2026?

Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued. The current stock price of kr1.01 is trading 12.2% above its estimated GF Value™ of kr0.90. GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.

Key valuation signals for OSTO:NXTCL:

  • Cyclically Adjusted Book per Share: kr1.55
  • GF Value™: kr0.90 vs. price of kr1.01 (12.2% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the OSTO:NXTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NextCell Pharma AB Business Description

Other Exchanges 65G:Germany
Address Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score

Get the complete analysis for OSTO:NXTCL

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.01
Price
kr0.90
GF Value